How Pharmaceutical-Grade Ketamine Tablet Is Made

How pharmaceutical-grade ketamine tablet is made depends on which product is being discussed. The injectable ketamine hydrochloride used in hospitals, and the raw material behind every compounded oral dose, is manufactured under FDA Current Good Manufacturing Practice (cGMP), a set of federal quality regulations that govern how licensed drug makers produce medications. The oral tablets, troches, and capsules patients actually take are different: no FDA-approved oral ketamine tablet exists on the U.S. market, so every oral dose comes from a compounding pharmacy working under USP General Chapter <795>, a pharmacy standard for preparing non-sterile, patient-specific medications that carries less mandatory testing than cGMP. Knowing which standard applies to a given ketamine product helps patients ask sharper questions of their prescriber and pharmacy.

Ketamine products reach patients through two different manufacturing systems, and mixing them up is common. Pharmaceutical manufacturing is large-scale, FDA-regulated production, the kind used to make the branded injectable Ketalar, built on validated processes and mandatory testing of every batch, following FDA Current Good Manufacturing Practice regulations. Compounding is small-scale, pharmacy-based preparation of a customized dose for an individual patient, and it is how nearly all oral compounded ketamine tablets and troches are produced today. Because no commercial oral ketamine tablet has FDA approval, pharmaceutical-grade standards currently apply mainly to the injectable API and to 503B outsourcing facilities, FDA-registered compounders that follow cGMP-like practices for larger, non-patient-specific batches.

Ketamine hydrochloride, the active pharmaceutical ingredient (API) in both injectable and compounded oral products, is produced through a multi-step chemical synthesis starting from cyclohexanone and other precursor chemicals. Manufacturers derivatize cyclohexanone, form the cyclohexamine ring structure, add a methylamino group through N-methylation, and convert the base compound to a hydrochloride salt. The resulting racemic mixture of R- and S-ketamine is then purified, dried, and milled to a specified particle size. Esketamine, marketed as Spravato, requires an added resolution step to isolate only the S-enantiomer. Before release, the API must meet the official ketamine monograph, including identity testing, related-substance limits, residual solvent limits, and an assay requirement. According to that monograph, ketamine HCl must test between 98.0-102.0% potency before a batch can be released for use. Reference chemical and pharmacokinetic data are cataloged in the PubChem database and in the clinical reference StatPearls: Ketamine.

If a company brings an FDA-approved oral ketamine tablet to market, formulation scientists would blend the active ketamine HCl with fillers such as microcrystalline cellulose, binders like hydroxypropyl methylcellulose, and disintegrants such as croscarmellose sodium to control how the tablet dissolves. Manufacturing would follow standard tablet production: blending the API and excipients for uniform distribution, granulating the mixture to improve flow, compressing it into tablets on high-speed presses, applying a film coating, and testing finished tablets for weight, hardness, dissolution, and content uniformity before packaging. Compounded troches follow a simpler process: the pharmacist weighs ketamine HCl on a calibrated balance, blends it into a molten polyethylene glycol or cocoa butter base, pours the mixture into molds, and assigns a beyond-use date, typically 30-180 days depending on the base and storage conditions.

The compounded ketamine tablet or troche a patient receives has not gone through the same testing as an FDA-approved drug, and quality can vary between pharmacies. PCAB accreditation, issued by the Pharmacy Compounding Accreditation Board, signals that a compounding pharmacy meets voluntary quality standards beyond the minimum a state board of pharmacy requires. It is reasonable to ask a compounding pharmacy whether it tests the potency of each ketamine batch and what beyond-use dating it assigns to its products. If an FDA-approved oral ketamine tablet reaches the market, it would carry the mandatory testing and stability data that compounded products do not currently require. For more on where regulatory review stands, see our guides on FDA status of oral ketamine and FDA considerations for ketamine tablets.